Composite prodrug nanocarrier for reversing tumor drug resistance and preparation method thereof

Abstract

The invention discloses a composite prodrug nanocarrier for reversing tumor drug resistance and a preparation method thereof, and belongs to the field of polymer materials and medical engineering. Thecomposite prodrug nanocarrier is formed by self-assembly of an amphiphilic pH-sensitive macromolecular prodrug and a superparamagnetic nanoparticle, and has a typical core-shell structure, the core of the composite prodrug nanocarrier is formed by coating a drug-coupled hydrophobic segment of an amphiphilic pH-sensitive macromolecular prodrug with the superparamagnetic nanoparticle, and the shellis formed by a hydrophilic segment of an amphiphilic pH-sensitive macromolecular prodrug. Since the composite prodrug nanocarrier uses the conditional responsive amphiphilic macromolecular prodrugtoreplace a conditional responsive amphiphilic macromolecule, the composite nanocarrier simultaneously has both efficient magnetic hyperthermia and targeted chemotherapy interference-free from magnetocaloric action, the magnetic hyperthermia and chemotherapy can be more effectively combined and targeted to tumor tissues, and effective reversal of tumor drug resistance can be ultimately achieved.

Description

technical field

[0001] The invention belongs to the field of polymer materials and medical engineering, and in particular relates to a multifunctional nano-drug carrier, in particular to a prodrug nano-carrier for reversing drug resistance of tumor drugs, which combines magnetic hyperthermia and pH-responsive chemotherapy . Background technique

[0002] The use of chemotherapeutic drugs to treat tumors is a routine means of tumor treatment at present, but clinical chemotherapy is often accompanied by the occurrence of tumor drug resistance, which is currently known as the most important reason for the failure of tumor chemotherapy. Tumor drug resistance can be divided into primary drug resistance and acquired drug resistance. Primary drug resistance means that tumor cells are not sensitive to certain chemotherapeutic drugs, and show drug resistance at the first administration. The acquired drug resistance is that after a period of chemotherapy, the remaining tumor cells ar...

Images